Disopyramide pharmacokinetics in the elderly after single oral administration. 1988

P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
Department of Pharmacology, University of Padova.

Disopyramide (D) kinetics were studied after single oral dose (200 mg) in ten elderly male patients (mean age: 75.5 yrs) without clinical or laboratory signs of hepatic, renal or cardiac disease, and in six healthy male subjects. They were all non smokers and had not taken alcohol for at least 10 days. Peak plasma concentration and area under the curve (AUCo-oo) were 54% and 51% respectively higher in the elderly group, whereas plasma half life was virtually the same in both groups (about 9 hrs). The major D metabolite, mono-N-desisopropyldisopyramide (MND), showed a tendency towards an increase of AUCo-24 h and T1/2 but did not reach the 5% significance level. Eight of the ten elderly patients but only two of the six young subjects complained of anticholinergic side effects. On the basis of the pharmacokinetic changes observed (and provided that plasma protein binding is unchanged), D oral dose should be reduced by 1/3, without modifying the dosage interval.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004206 Disopyramide A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. Diisopyramide,Disopyramide Monohydrochloride,Disopyramide Phosphate,Disopyramide Phosphate (1:1),Disopyramide Phosphate (1:1), (+-)-Isomer,Disopyramide Phosphate (1:1), (R)-Isomer,Disopyramide Phosphate (1:1), (S)-Isomer,Disopyramide, (+-)-Isomer,Disopyramide, (R)-Isomer,Disopyramide, (S)-Isomer,Disopyramide, D-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:1), (R)-Isomer,Disopyramide, L-Tartrate (1:1), (S)-Isomer,Disopyramide, L-Tartrate (1:2), (+-)-Isomer,Disopyramide, L-Tartrate, (S)-isomer,Norpace,Palpitin,Palpitine,Rhythmodan,Ritmilen,Rythmilen,SC-13957,SC 13957,SC13957
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
January 1984, European journal of clinical pharmacology,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
January 1979, The Medical journal of Australia,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
July 1991, Journal of pharmaceutical sciences,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
December 2011, Journal of veterinary pharmacology and therapeutics,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
December 2011, Veterinary dermatology,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
March 1990, Leukemia,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
June 1984, Journal of pharmacokinetics and biopharmaceutics,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
January 1990, European journal of clinical pharmacology,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
October 1983, Ugeskrift for laeger,
P Roberto, and B Vitaliano, and P Donatella, and M Raffaella, and B Sergio, and C Gabriella
January 2003, Arzneimittel-Forschung,
Copied contents to your clipboard!